O simpósio “Balancing tolerability and efficacy in CML: strategies to improve long-term outcomes in the newly diagnosed setting”, promovido pela Novartis, decorreu no âmbito da 27th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, organizado pela European School of Haematology e pela International Chronic Myeloid Leukemia Foundation.…
Por favor faça login ou registe-se para aceder a este conteúdo

